{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypercholesterolaemia-familial/prescribing-information/ezetimibe/","result":{"pageContext":{"chapter":{"id":"8007ba2c-d902-5e52-9fb3-1aedd9470650","slug":"ezetimibe","fullItemName":"Ezetimibe","depth":2,"htmlHeader":"<!-- begin field 3680db09-4497-418e-be5e-74831d33e325 --><h2>Ezetimibe</h2><!-- end field 3680db09-4497-418e-be5e-74831d33e325 -->","summary":"","htmlStringContent":"<!-- begin item 4751124c-ceb6-4985-bb99-2401f4386d46 --><!-- end item 4751124c-ceb6-4985-bb99-2401f4386d46 -->","topic":{"id":"e1e436f3-28ca-5b97-8fd7-0156f61bfd7c","topicId":"030641a4-5f0a-4edf-a3ac-c21903c0095e","topicName":"Hypercholesterolaemia - familial","slug":"hypercholesterolaemia-familial","lastRevised":"Last revised in September 2020","chapters":[{"id":"23ce1270-bfbc-5ded-ab6d-c230787a3f98","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1ac01f09-287f-5fd1-a1a5-3392235af19a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a92fc8a9-1061-5c02-bfff-d5f934ffdb53","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"93e2888f-005e-50e1-8f04-9c8023c43019","slug":"changes","fullItemName":"Changes"},{"id":"4cd7461b-b74a-5b4a-bbf9-499684c190d6","slug":"update","fullItemName":"Update"}]},{"id":"ebac4860-8279-5daa-8053-2376a8a9d71d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"18209ebb-2e72-5f12-879c-4cac6c4a4a74","slug":"goals","fullItemName":"Goals"},{"id":"db603b52-871f-5820-9fbc-8fa05bcd0c1c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"107217fb-afa8-59f5-b492-20a089b4ff48","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55a1140b-b028-5056-9c88-5836bc15dd3b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef31a150-3669-5487-b7f5-e19d13bf639e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00bd8dc2-4dee-5ba6-a759-82c99a58cd4d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2cc20b8e-5159-51e2-b31b-9d3f16bcff36","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ec5f41d9-1fa0-53f1-aaee-0b37d62682af","slug":"definition","fullItemName":"Definition"},{"id":"687776fd-3a40-5dcf-ada0-1e58ff0f3128","slug":"causes","fullItemName":"Causes"},{"id":"cb1847cd-3321-5104-a764-beaf8c58397c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"63b1cca3-87f7-5577-af56-fb3b38977e30","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"13588941-b46f-5306-a752-0527c4458410","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4be7f4e2-6458-5112-948b-50b0e98bbb7a","slug":"identification","fullItemName":"Identification"},{"id":"343de6bd-ed4d-5fcc-b7d7-7ca1565daf0d","slug":"assessment-diagnosis","fullItemName":"Assessment and diagnosis"}]},{"id":"13ac6594-5e56-502b-96f4-2f848eb59c83","fullItemName":"Management","slug":"management","subChapters":[{"id":"2349db0e-12d5-5ff8-8e14-2e885307ad42","slug":"adults-with-heterozygous-fh","fullItemName":"Scenario: Adults with heterozygous FH"},{"id":"2f9228e9-d4af-55d1-937d-74e9c83e418e","slug":"adults-with-homozygous-fh","fullItemName":"Scenario: Adults with homozygous FH"},{"id":"c8ba3d52-d1bc-5e22-a366-a32ab938db00","slug":"children-young-people-with-fh","fullItemName":"Scenario: Children and young people with FH"}]},{"id":"323963cd-05be-519c-a523-3922e41f11f0","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c555b9e-f39b-567f-89ff-c983ab785087","slug":"statins-atorvastatin-rosuvastatin-simvastatin","fullItemName":"Statins (atorvastatin, rosuvastatin, and simvastatin)"},{"id":"8007ba2c-d902-5e52-9fb3-1aedd9470650","slug":"ezetimibe","fullItemName":"Ezetimibe"}]},{"id":"189143bc-5ae2-58d6-83ae-e0cd9bc01ee6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"efd82555-8ecb-5170-be69-2e7390295832","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"652a4e82-a231-5cb4-8c7c-563ca0f43bbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"2be02b62-6acf-5570-854e-e6dcbfb36426","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7d6217e2-3ab0-516c-97eb-53f4083e8805","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2ce56158-d459-5b28-8343-7b6d776dc77a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3f7dd940-f042-5f4d-8968-a8002af95e8d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ca7fcd28-909d-579e-8783-9249cd67764f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"323963cd-05be-519c-a523-3922e41f11f0","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"752046f4-c6a7-5664-a096-aed3e7f2a4e7","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 5d67a7b2-6f13-4b68-a419-3d4a9aee1b30 --><h3>What are the contraindications and cautions for ezetimibe?</h3><!-- end field 5d67a7b2-6f13-4b68-a419-3d4a9aee1b30 -->","summary":"","htmlStringContent":"<!-- begin item 7873ab7a-7a7a-4fc0-98cc-c205cb7b4232 --><!-- begin field 11efa540-4437-4d00-84cb-f3f58defcc8b --><ul><li><strong>Do not prescribe ezetimibe to:</strong><ul><li>People with stage 4 or 5 chronic kidney disease (CKD, estimated glomerular filtration rate [eGFR] less than 30 mL/minute/1.73 m<sup>2</sup>).</li><li>Breastfeeding women — it is not known if ezetimibe is secreted into human breast milk, but studies on rats have shown that it is secreted into breast milk.</li><li>People who are also taking a statin and:<ul><li>Are pregnant or breastfeeding.</li><li>Have active liver disease or unexplained persistent elevations in serum transaminases.</li></ul></li></ul></li><li><strong>Prescribe ezetimibe with caution to:</strong><ul><li>Pregnant women — the manufacturer advises use only if potential benefit outweighs risk as there are no clinical data on the use of ezetimibe during pregnancy. However, animal studies have shown no evidence of direct or indirect harmful effects on pregnancy, embryofetal development, birth, or postnatal development.</li><li>People with predisposing factors for rhabdomyolysis, such as concomitant use with an <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/prescribing-information/ezetimibe/#drug-interactions\">interacting</a> drug, CKD, hypothyroidism, and personal or family history of hereditary muscular disorders.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">ABPI, 2018b</a>]</p><!-- end field 11efa540-4437-4d00-84cb-f3f58defcc8b --><!-- end item 7873ab7a-7a7a-4fc0-98cc-c205cb7b4232 -->","subChapters":[]},{"id":"c594520b-a25f-58ea-bf80-fe514e7416e8","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 3efa9c63-fd4e-433f-b172-604adc062f8c --><h3>What are the adverse effects of ezetimibe?</h3><!-- end field 3efa9c63-fd4e-433f-b172-604adc062f8c -->","summary":"","htmlStringContent":"<!-- begin item b0ebf691-8b82-458a-aa1e-d4384986c3da --><!-- begin field 0884c99d-1cc6-4392-8ab9-c96823918285 --><ul><li><strong>Common or very common </strong><strong><strong>adverse effects of ezetimibe include</strong> </strong>asthenia, diarrhoea, gastrointestinal discomfort, and gastrointestinal disorders.</li><li><strong>Other adverse effects include:</strong><ul><li><strong>Uncommon </strong>— appetite decreased, arthralgia, chest pain, cough, hot flush, hypertension, muscle complaints, nausea, and pain.</li><li><strong>Frequency not known </strong>— constipation, depression, dizziness, dyspnoea, hepatitis, myopathy, pancreatitis, paraesthesia, skin reactions, and thrombocytopenia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">BNF 76, 2018</a>] </p><!-- end field 0884c99d-1cc6-4392-8ab9-c96823918285 --><!-- end item b0ebf691-8b82-458a-aa1e-d4384986c3da -->","subChapters":[]},{"id":"1d0bd8dc-d884-565d-92ed-75c6319c4832","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field f9374018-8506-475b-80d3-2de122ee0dda --><h3>What drug interactions are associated with ezetimibe?</h3><!-- end field f9374018-8506-475b-80d3-2de122ee0dda -->","summary":"","htmlStringContent":"<!-- begin item 3c3a5b58-ff0e-4d3b-9c9b-b481769dbe43 --><!-- begin field 1f40c84a-d6d1-44b9-8e8c-faa718121334 --><ul><li><strong>Drug interactions associated with ezetimibe include:</strong><ul><li><strong>Ciclosporin </strong>— plasma concentration of both drugs may increase when ezetimibe is given with ciclosporin.<ul><li>Concurrent use should be done cautiously, and ciclosporin concentrations should be monitored.</li></ul></li><li><strong>Fibrates </strong>—<strong> </strong>predicted to increase the risk of gallstones when given with ezetimibe.<ul><li>Manufacturer advises discontinue if gallstones develop.</li></ul></li><li><strong>Statins</strong> — ezetimibe potentially increases the risk of rhabdomyolysis when given with statins.<ul><li>Monitor concurrent use closely.</li></ul></li><li><strong>Warfarin </strong>— there have been post-marketing reports of increased international normalized ratio (INR) in people who had ezetimibe added to warfarin.<ul><li>If concurrent use is necessary, monitor INR closely.</li></ul></li></ul></li><li><strong>For a complete list of possible drug interactions of ezetimibe, </strong>see the <a data-hyperlink-id=\"5d1bd39e-1a5d-4822-a304-a98f017ff9da\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"eadda68c-df0e-46e1-aaa7-a98f017ffaca\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">BNF 76, 2018</a>] </p><!-- end field 1f40c84a-d6d1-44b9-8e8c-faa718121334 --><!-- end item 3c3a5b58-ff0e-4d3b-9c9b-b481769dbe43 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}